A review of cardiovascular benefits of SGLT2 inhibitors

被引：3
|
作者：
Zhang, Yingxia [1 ]
Han, Qinghua [2 ]
机构：
[1] Shanxi Med Univ, Key Lab Cellular Physiol, Dept Clin Med 1, Minist Educ, Taiyuan, Shanxi, Peoples R China
[2] Shanxi Med Univ, Key Lab Cellular Physiol, Dept Cardiol, Minist Educ,Hosp 1, 85 South Jiefang Rd, Taiyuan 030001, Shanxi, Peoples R China
来源：
MEDICINE | 2022年 / 101卷 / 36期
关键词：
arrhythmia; cardiomyopathy; heart failure; hypertension; mechanism; myocardial infarction; sodium-glucose cotransporter 2 inhibitor; MYOCARDIAL-INFARCTION; DOUBLE-BLIND; EMPAGLIFLOZIN; DAPAGLIFLOZIN; RISK; CARDIOPROTECTION; CANAGLIFLOZIN; ASSOCIATION; DISEASES; DEATH;
D O I：
10.1097/MD.0000000000030310
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Sodium-glucose cotransporter 2 inhibitor (SGLT2I) is a new type of hypoglycemic drug that targets the kidney. As research continues to advance on this topic, it has been found that SGLT2I has multiple protective effects, such as hypoglycemic, cardio-renal protective, antihypertensive, and lipid-lowering effects. This review discusses the current concepts and possible mechanisms of SGLT2I in the treatment of heart failure, myocardial infarction, hypertension, cardiomyopathy and arrhythmia to provide a reference for clinicians to use drugs more reasonably and scientifically.
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review
    Rabizadeh, Soghra
    Nakhjavani, Manouchehr
    Esteghamati, Alireza
    [J]. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2019, 17 (02)
  • [2] Investigating Cardiovascular Benefits of SGLT2 Inhibitors
    Sieracki, Lauren
    Sordi, Christina
    Ostroff, Marissa L.
    Ostroff, Jared L.
    [J]. US PHARMACIST, 2022, 47 (11) : 17 - 22
  • [3] Possible mechanisms of cardiovascular benefits of SGLT2 inhibitors
    Verges, B.
    [J]. ARCHIVES OF CARDIOVASCULAR DISEASES SUPPLEMENTS, 2019, 11 : S18 - S22
  • [4] Benefits of SGLT2 inhibitors in arrhythmias
    Gao, Jinghan
    Xue, Genlong
    Zhan, Ge
    Wang, Xinying
    Li, Jiatian
    Yang, Xiaolei
    Xia, Yunlong
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [5] SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits
    Preda, Alberto
    Montecucco, Fabrizio
    Carbone, Federico
    Camici, Giovanni G.
    Luscher, Thomas F.
    Kraler, Simon
    Liberale, Luca
    [J]. CARDIOVASCULAR RESEARCH, 2024, 120 (05) : 443 - 460
  • [6] SGLT2 Inhibitors: Benefits for CKD and Cardiovascular Disease in Type 2 Diabetes
    Singhal, Rohit
    Hechanova, Lisa Aimee
    [J]. CURRENT CARDIOLOGY REPORTS, 2022, 24 (03) : 183 - 189
  • [7] SGLT2 Inhibitors: Benefits for CKD and Cardiovascular Disease in Type 2 Diabetes
    Rohit Singhal
    Lisa Aimee Hechanova
    [J]. Current Cardiology Reports, 2022, 24 : 183 - 189
  • [8] Cardiovascular safety of SGLT2 inhibitors
    Gumprecht, Janusz
    [J]. CLINICAL DIABETOLOGY, 2016, 5 (02): : 62 - 65
  • [9] Cardiovascular benefit of SGLT2 inhibitors
    Mohebi, Reza
    Januzzi, James L.
    [J]. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2022, 59 (03) : 142 - 155
  • [10] SGLT2 inhibitors in cardiovascular medicine
    Varzideh, Fahimeh
    Kansakar, Urna
    Santulli, Gaetano
    [J]. EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2021, 7 (04) : E67 - E68
12345